Details for Patent: 8,246,989

Title:	Dosage forms of bisphosphonates
Abstract:	Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.
Inventor(s):	Dansereau; Richard John (Cincinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH)
Assignee:	Warner Chilcott Company, LLC (Fajardo, PR)
Filing Date:	Dec 14, 2009
Application Number:	12/637,100
Claims:	1. An oral dosage form comprising: (a) about 35 mg of a risedronate salt; (b) about 100 mg of EDTA or a pharmaceutically acceptable salt thereof; and (c) a delayed release mechanism to deliver the risedronate salt and EDTA or pharmaceutically acceptable salt thereof to the lower GI tract. 2. The oral dosage form of claim 1, wherein the oral dosage form is a tablet comprising a core containing the risedronate salt and EDTA or pharmaceutically acceptable salt thereof. 3. The oral dosage form of claim 2, wherein the delayed release mechanism is a pH dependent enteric coating. 4. The oral dosage form of claim 3, wherein the risedronate salt is risedronate sodium. 5. The oral dosage form of claim 4, wherein the EDTA or pharmaceutically acceptable salt thereof is disodium EDTA. 6. The oral dosage form of any one of claims 3, 4 or 5, wherein the pH dependent enteric coating comprises a methacrylic acid copolymer. 7. The oral dosage form of claim 6, wherein the methacrylic acid copolymer is selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2. 8. The oral dosage form of claim 7, wherein the methacrylic acid copolymer is poly(methacrylic acid, ethyl acrylate) 1:1. 9. The oral dosage form of any one of claims 3, 4 or 5, wherein the pH dependent enteric coating does not entirely dissolve or disintegrate until the dosage form enters the small intestine. 10. The oral dosage form of any one of claims 3, 4 or 5, wherein the pH dependent enteric coating is comprised of a partly methyl-esterified methacrylic acid polymer. 11. The oral dosage form of claim 10, wherein a ratio of free anionic carboxyl groups to ester groups of the partly methyl-esterified methacrylic acid polymer is about 1:1. 12. The oral dosage form of any one of claims 3, 4 or 5, wherein the pH dependent enteric coating is about 5 to 50% of the weight of the core of the tablet. 13. The oral dosage form of any one of claims 3, 4 or 5, wherein the pH dependent enteric coating is comprised of a polymer selected from the group consisting of methyl acrylate-methacrylic acid copolymers, hydroxyl propyl methyl cellulose phthalate, cellulose acetate phthalate, polyvinyl acetate phthalate, shellac, cellulose acetate succinate and cellulose acetate trimellate. 14. The oral dosage form of any one of claims 3, 4 or 5, wherein the pH dependent enteric coating dissolves in gastrointestinal fluid at a pH of 5.5 or above. 15. The oral dosage form of claim 1, wherein the oral dosage is comprised of granules comprised of the risedronate salt and EDTA or pharmaceutically acceptable salt thereof, and wherein the delayed release mechanism is a pH dependent enteric coating of the granules. 16. The oral dosage form of claim 15, wherein the dosage form is a tablet. 17. The oral dosage form of claim 16, wherein the risedronate salt is risedronate sodium. 18. The oral dosage form of claim 17, wherein the EDTA or pharmaceutically acceptable salt thereof is disodium EDTA. 19. The oral dosage form of any one of claims 15, 16 or 17, wherein the pH dependent enteric coating comprises a methacrylic acid copolymer. 20. The oral dosage form of claim 19, wherein the methacrylic acid copolymer is selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2. 21. The oral dosage form of claim 20, wherein the methacrylic acid copolymer is poly(methacrylic acid, ethyl acrylate) 1:1. 22. The oral dosage form of any one of claims 15, 16 or 17, wherein the pH dependent enteric coating does not entirely dissolve or disintegrate until the dosage form enters the small intestine. 23. The oral dosage form of any one of claim 15, 16 or 17, wherein the pH dependent enteric coating is comprised of a partly methyl-esterified methacrylic acid polymer. 24. The oral dosage form of claim 23, wherein a ratio of free anionic carboxyl groups to ester groups of the partly methyl-esterified methacrylic acid polymer is about 1:1. 25. The oral dosage form of any one of claims 15, 16 or 17, wherein the pH dependent enteric coating is about 10 to 75% of the weight of the granules. 26. The oral dosage form of any one of claims 15, 16 or 17, wherein the pH dependent enteric coating is comprised of a polymer selected from the group consisting of methyl acrylate-methacrylic acid copolymers, hydroxyl propyl methyl cellulose phthalate, cellulose acetate phthalate, polyvinyl acetate phthalate, shellac, cellulose acetate succinate and cellulose acetate trimellate. 27. The oral dosage form of any one of claims 15, 16 or 17, wherein the pH dependent enteric coating dissolves in gastrointestinal fluid at a pH of 5.5 or above.